title: Increased concentrations of prostaglandin D2 during post-fracture bone remodeling.
abstract: OBJECTIVE
  To test the hypothesis that increased concentrations of prostaglandin D(2) (PGD(2)) correlate with bone remodeling. Studies using isolated bone cells indicate that PGD(2) may be implicated in the regulation of bone homeostasis, with a positive influence on bone anabolism. We studied patients with traumatic fractures and age- and sex-matched healthy controls as an in vivo model of increased bone remodeling.
  
  
  METHODS
  Thirty-five patients with bone fracture and matched controls were recruited. Urine and sera samples were collected. Urinary 11ss-PGF(2alpha), a PGD(2) metabolite, and PGE(2) metabolites (PGEM), serum lipocalin-type PGD(2) synthase (L-PGDS), bone alkaline phosphatase (bone ALP), and crosslinked C-telopeptides of type I collagen (CTX) were measured.
  
  
  RESULTS
  At 5-6 weeks post-fracture, 11ss-PGF(2alpha), L-PGDS, bone ALP, and CTX were significantly increased in the fracture patients compared to controls. PGEM levels were not different between groups. Levels of 11ss-PGF(2alpha) and bone ALP were positively correlated, suggesting that PGD(2) may be implicated in fracture repair.
  
  
  CONCLUSIONS
  These results support our working hypothesis that PGD(2) could be implicated in the control of bone anabolism in humans.
authors.affiliation: Division of Rheumatology, Centre de Recherche Clinique Etienne-Le Bel, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada.
authors.forename: Maxime A
authors.initials: MA
authors.lastname: Gallant
authors.forename: Estelle
authors.initials: E
authors.lastname: Chamoux
authors.forename: Martine
authors.initials: M
authors.lastname: Bisson
authors.forename: Catarina
authors.initials: C
authors.lastname: Wolsen
authors.forename: Jean-Luc
authors.initials: JL
authors.lastname: Parent
authors.forename: Sophie
authors.initials: S
authors.lastname: Roux
authors.forename: Artur J
authors.initials: AJ
authors.lastname: de Brum-Fernandes
mesh_terms: D000293:Adolescent; D000328:Adult; D000469:Alkaline Phosphatase / Q000378:metabolism; D016723:Bone Remodeling / Q000502:physiology*; D001842:Bone and Bones / Q000378:metabolism; D016022:Case-Control Studies; D024042:Collagen Type I; D015237:Dinoprost / Q000378:metabolism; D015232:Dinoprostone / Q000378:metabolism; D005260:Female; D050723:Fractures, Bone / Q000378:metabolism*; D006706:Homeostasis / Q000502:physiology; D006801:Humans; D019746:Intramolecular Oxidoreductases / Q000378:metabolism; D054834:Lipocalins / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000378:metabolism; D010455:Peptides; D011347:Procollagen / Q000378:metabolism; D015230:Prostaglandin D2 / Q000378:metabolism*; D055815:Young Adult
chemical_list: D024042:Collagen Type I; D054834:Lipocalins; D010446:Peptide Fragments; D010455:Peptides; D011347:Procollagen; C052929:collagen type I trimeric cross-linked peptide; D015237:Dinoprost; D000469:Alkaline Phosphatase; D019746:Intramolecular Oxidoreductases; C022466:prostaglandin R2 D-isomerase; D015232:Dinoprostone; D015230:Prostaglandin D2